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 Introduction 
 Vascular lesions of the face represent an aesthetic 
problem and are a symptom of different skin diseases  [1] . 
Currently, laser technology can be considered an effective 
treatment modality for superficial vascular lesions of the 
face using light sources with visible (500–800 nm) and 
near-infrared (800–1,300 nm) wavelengths  [2] . Initially, 
the most widely used systems to treat these lesions were 
potassium titanyl phosphate (KTP, 532 nm), the copper 
vapor laser (511/578 nm), the alexandrite laser (755 nm) 
and the diode laser (800/810/930 nm). The current sys-
tems such as the dye laser (595 nm), Nd:Yag laser (1,064 
nm) and pulsed-light system (500–1,200 nm) were then 
introduced  [3] . 
 The choice of an effective laser for treating vascular le-
sions should take into account the wavelength at which 
the vascular chromophore has the greatest absorption; 
these devices focus on oxyhemoglobin which has 3 wave-
length absorption peaks, i.e. at 418, 542 and 577 nm 
( fig. 1 )  [4] .
 Rhodamine intense pulsed light (r-IPL) is a new 
pulsed-light system optimized for wavelengths ranging 
between 550 and 650 nm, which can achieve performanc-
es comparable to those of the dye laser (595 nm). The r-
IPL handpiece uses rhodamine as a fluorescent substance 
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 Abstract 
 Objective: The aim of this work was to verify the usefulness 
and efficacy of treating superficial vascular lesions of the face 
using rhodamine intense pulsed light (r-IPL).  Subjects and 
Methods: Fifty patients suffering from telangiectasias of the 
face were enrolled and subsequently treated 4 times (every 
20 days) with a new intensified r-IPL system optimized at the 
same wavelength as the dye laser (595 nm). The outcome 
was assessed using photographs, and clinical evaluations 
were made based on the percentage of fading of the ery-
thema and telangiectasias in the lesions after treatment.  Re-
sults: Marked clinical improvements (70–100%) were ob-
served in 31 (62%) patients after the second session of r-IPL, 
while 46 (92%) showed a marked improvement after the 
fourth session. No patients had to resort to topical or sys-
temic drugs.  Conclusion: r-IPL  was effective in treating su-
perficial vascular lesions, no side effects were observed and 
the patients readily accepted the treatment. Hence, r-IPL 
could be promising for the treatment of superficial vascular 
lesions of the face. Future study would be necessary to con-
firm the long-term efficacy of this technique. 
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that can absorb wavelengths in the UV spectrum up to 
550 nm and re-emit these in fluorescence in a range of 
between 550 and 650 nm, with a rhodamine peak at ap-
proximately 570 nm, without losing energy during the 
transformation ( fig. 2 ). This system of shifting the emis-
sion band via fluorescence can also exploit the compo-
nent closest to the UV spectrum (between 450 and 500 
nm) not selected for vascular lesions. This range of wave-
lengths would not produce therapeutic effects and cause 
interactions in the pigmentary component only, so it is 
usually eliminated in traditional pulsed-light systems 
through the use of filters. The r-IPL technology does not 
eliminate a significant amount of energy, but rather trans-
fers it to a vascular frequency range, as for dye laser spec-
ifications, in order to increase both energy efficiency and 
performance on the hemoglobin chromophore ( fig. 3 ).
 The use of waveguides, which transfer the energy that 
is generated, and subsequently optimized, into the tissue, 
allows the handpiece to be moved away from the skin to 
increase treatment area visibility. The handpiece can be 
adapted to effectively reach every area of the face includ-
ing those hardest to access, such as the base of the nose. 
As in other laser systems, optimized cooling of the wave-
guide protects the epidermis against pulsed-light radia-
tion, thereby maintaining the integrity of the surround-
ing tissue. Cooling is also used to generate a local anes-
thetic effect over the radiated area, making the treatment 
more comfortable. The aim of this study was to verify the 
usefulness and effectiveness of r-IPL and to demonstrate 
if it can indeed merge the advantages of IPL and laser de-
vices in treating superficial vascular lesions of the face.
 Subjects and Methods 
 A total of 50 patients (29 females and 21 males, aged between 
30 and 60 years), of skin phototypes I–IV and suffering from tel-
angiectasias of the face, were examined and subsequently treated 
in our university-based Dermatology Outpatient Clinic from Oc-
tober 2013 to November 2014. Patients were suffering from com-
mon telangiectasias (n = 23), facial erythrosis (n = 11), acne rosacea 
(n = 7) or telangiectasias of the nose (n = 5) and chin (n = 4). The 
study was carried out according to the principles of the Declaration 
of Helsinki and was approved by the Institutional Review Board. 
Written informed consent was obtained from each patient for the 
treatment and release of photographic images for scientific pur-
poses. 
400 450 500 550 600 650 700 750 800 Wavelength (nm)
Oxyhemoglobin
Deoxyhemoglobin
Dye laser range
Melanin
 Fig. 1. Absorption spectrum of the main skin chromophores and 
hemoglobin selectivity of the dye laser. 
450 500 550 600 650 700 750 800 Wavelength (nm)
IPL without rhodamine light
IPL with rhodamine light
Dye laser range
 Fig. 2. Emission frequencies of IPL, rhodamine light and dye laser. 
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 Fig. 3. Increase in vascular performance of r-IPL on the hemoglo-
bin cromophore. 
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 The study treatment protocol involved the use of a new system, 
a rhodamine light handpiece (DEKA M.E.L.A srl, Florence, Italy), 
which exploits rhodamine as a selective fluorescent substance for 
the vascular target. Two handpieces were available with an emis-
sion area of 2 and 6.2 cm 2 , respectively, and supplied with an in-
tegrated cooling system. All the patients were subjected to an ef-
fectiveness check during the first visit (October 2013 to August 
2014) and subsequently treated every 20 days for a total of 4 treat-
ments. The protocol provided fluencies ranging between 18 and 
23 J/cm 2 , with an emission area of 2 or 6.2 cm 2 , selected according 
to the severity and size of the lesions. We usually started with a 
low fluency of 18 J/cm 2 , which was gradually increased in subse-
quent sessions to up to 23 J/cm 2 . Two pulses of 6–8 ms each were 
performed with a delay of 10 ms between pulses. Conductive cold 
gel for pulsed light was placed between the crystal and the light to 
provide optimal contact and heat dispersion. Not much pressure 
was exerted during treatment so as to avoid causing any vessel 
ischemia. Patients were photographed before the first treatment 
and at the end of the therapy with a digital camera system, Anthol-
ogy (DEKA M.E.L.A. srl), and with Antera 3D (Miravex Ltd., 
Dublin, Ireland), a noninvasive photographic device that uses a 
multisource spectrum and 3-dimensional mapping of the skin 
surface and is able to analyze both the hemoglobin and melanin 
skin components. It was thus possible to estimate the length and 
width of the capillaries, the area of the lesion and the concentra-
tion of hemoglobin with the Antera system. The most extensively 
vascularized areas showed in the pictures in colors ranging from 
red to purple. All images were evaluated on 2 databases (Anthol-
ogy and Antera 3D) in order to verify the efficacy of r-IPL on the 
vascular pattern. 
 The outcomes were evaluated from photographs taken by in-
dependent clinical observers (G.C. and R.C.), i.e. not the operator 
dermatologist. Based on the percentage of fading of the erythema 
and telangiectasias in the lesions after treatment, they were divided 
into 4 categories: no outcomes (0%), a slight improvement (1–
40%), a moderate improvement (40–70%) and a marked improve-
ment (70–100%).
 Both during and after therapy, the patients were asked to quan-
tify the perceived pain as mild, moderate or severe. A clinical eval-
uation of transient erythema and posttreatment edema was carried 
out by a dermatologist (R.C.) and identified as absent, mild or in-
tense.
 Results 
 The mean age of the 50 patients was 44.6 + 15.3 years. 
A marked clinical improvement was observed in 31 (62%) 
of the 50 lesions after the second session of r-IPL, and 46 
(92%) showed a marked improvement after the fourth 
session ( fig. 4 ;  table 1 ). The outcomes are highlighted in 
 figures 5–8 , where clinical pictures taken before and after 
the treatment are compared with the images obtained 
with the Antera system.
 All the patients tolerated the treatment well, 78% re-
ported mild pain and 22% reported moderate pain that 
lasted a few minutes during and after the treatment. No 
patients underwent systemic antibiotic or corticosteroid 
therapy and there were no side effects.
 In the immediate posttreatment period, slight tran-
sient erythema and edema were reported, which were 
treated with simple soothing creams. 
 Discussion 
 The treatment of facial telangiectasias is ever more fre-
quently performed by laser or IPL devices. In this study, 
we demonstrate the efficacy and the safety of r-IPL for 
treating superficial vascular lesions of the face, combining 
the advantages of dye laser and IPL. 
 Dye laser is the mainstay of treatment of vascular le-
sions such as facial telangiectasias because of its high de-
gree of safety and efficacy  [5–8] . Despite its excellent re-
sults, the appearance of clear, purple bruises and subse-
quent scabbing in the posttreatment period that continue 
Second session
No results
Slight improvement
Moderate improvement
Marked improvement
Fourth session
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40
50
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80
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%
 Fig. 4. Overall improvement assessment. 
 Table 1.  Marked improvement at the fourth session
Disorder Patients showing a
marked improvement at 
the fourth session, n (%)
Common telangiectasia 23 (100)
Facial erythrosis 10 (90.9)
Acne rosacea 6 (85.7)
Telangiectasia of the nose 4 (80)
Telangiectasia of the chin 3 (75)
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for several days could significantly limit its acceptance by 
patients who are treated for an aesthetic disease like tel-
angiectatic rosacea. Conversely, according to our experi-
ence, treatment with r-IPL is not followed by the appear-
ance of long-lasting purpura but only by transient ery-
thema and edema which did not limit the patients’ daily 
activities.
 Several studies have demonstrated that IPL is another 
effective alternative or complementary therapeutic pre-
sidium to vascular laser  [9–12] . IPL emits a polychromat-
ic noncoherent broad-band light (500–1,200 nm). Its 
emission can, however, be made more selective by using 
proper filters and directing it towards specific chromo-
phores such as melanin and hemoglobin  [13] . The advan-
tages of this technology are that it can hit the vascular 
target localized at different depths and with different 
wavelengths. Conversely, the most significant limitation 
of IPL is that more energy is released within the infrared 
spectrum, leaving little energy in the visible spectrum 
where the maximum peaks for hemoglobin absorptions 
are located, as is achieved with the dye laser  [14] . Accord-
ing to our experience, r-IPL has proven to enhance per-
a b
 Fig. 5. Clinical images of a patient with
facial telangiectasia.  a Before treatment.
 b After 4 treatments with r-IPL, there was 
a marked improvement. 
a b
c d
 Fig. 6. Marked improvement in a patient 
with severe telangiectasia and erythrosis of 
the face. Before treatment: clinical image 
( a ) and image obtained with Antera ( b ). 
After 4 treatments with r-IPL, the clinical 
image ( c ) and images obtained with Antera 
( d ) show a marked improvement. 
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a b
c d
a b
c d
 Fig. 7. Patient with erythrosis and fine tel-
angiectasia of the cheeks. Before treatment: 
clinical image ( a ) and image obtained with 
Antera ( b ). After 4 treatments with r-IPL, 
the clinical image ( c ) and images obtained 
with Antera ( d ) show a marked improve-
ment. 
 Fig. 8. Another patient with telangiectasia 
of the cheeks. Before treatment: clinical im-
age ( a ) and image obtained with Antera 
( b ). After 4 treatments with r-IPL, the clin-
ical image ( c ) and image obtained with An-
tera ( d ) show a marked improvement. 
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formance in the working range of dye laser systems, 
thereby allowing greater outputs of energy at vascular 
wavelengths with no side effects.
 In our study, marked improvements were observed in 
the majority of patients after the second session and in 
almost all of the patients after the fourth session. After the 
treatments, patients did not have to resort to topical or 
systemic drugs, so all of them showed excellent compli-
ance during all 4 treatments established according to the 
protocol. 
 Thus, conversely to the other laser or light therapies, 
rhodamine light  did not result in any side effects and pa-
tients readily accepted the treatment. 
 A limitation of this study was the absence of a long-
term monitoring of the patients that would have demon-
strated the efficacy of this technique over a long period.
 Conclusion 
 Our study showed that r-IPL did not have any report-
ed side effects and also had an excellent outcome in all 
patients. These benefits could make this form of IPL 
promising for the treatment of superficial vascular lesions 
of the face. The absence of intense erythema and scabs al-
lows us to suggest that higher fluencies may be used in 
order to obtain the same results in a smaller number of 
treatments. This aspect will need to be verified in future 
studies.
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